Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Ars Pharmaceutica (Internet)
versión On-line ISSN 2340-9894
Resumen
MAKHMALZADE, Behzad Sharif; KARAMI, Masoud Ali y RAD, Narges Mosaddegh. Preparation and characterization of topical solid lipid nanoparticles containing deferoxamine. Ars Pharm [online]. 2021, vol.62, n.3, pp.224-234. Epub 27-Sep-2021. ISSN 2340-9894. https://dx.doi.org/10.30827/ars.v62i3.15493.
Introduction:
Deferoxamine mesylate increases hypoxia inducible factor-1 alpha transactivation by preventing iron-catalyzed reactive oxygen stress, so it can be used to improve diabetic ulcer healing. This study was undertaken to develop and study physicochemical properties of topical deferoxamine-loaded solid lipid nanoparticles.
Method:
Solid lipid nanoparticles were prepared using cold homogenization technique and full factorial design to evaluate the effect of surfactant type and amount of lipid. In-vitro characterization of formulations including particle size and distribution, thermal behavior using Differential Scanning Calorimetry, entrapment efficiency, and release profile were carried out.
Results:
The results showed an acceptable range of particle size (2.88-174 nm), a narrow size distribution, and an average of 60% for drug entrapment efficiency which is significant for a hydrophilic drug. The results from release study showed an initial burst release followed by a slow and prolonged manner. Differential Scanning Calorimetry results also confirmed the results obtained from loading and release evaluations. The best formulation which had a high level of drug loading and the lowest drug release rate contained compritol and oleic acid in the amount of 8% of the total formula, as well as tween 80 and lecithin as a mixture of surfactants.
Conclusions:
The study demonstrated deferoxamine could be loaded in solid lipid nanoparticles to deliver topically.
Palabras clave : Deferoxamine mesylate; Solid Lipid Nanoparticles; Topical formulation deliver.